CNS International Prognostic Index in Diffuse Large B-Cell Lymphoma (CNS-IPI)

Estimate risk of CNS relapse/progression in diffuse large B-cell lymphoma

The global unit selector only affects unanswered questions
1.Age?
2.Performance Status?
3.LDH?
4.Extranodal Sites?
5.Stage?
6.Kidney and/or Adrenal involvement?
Created by

1. Age?

Created by
0/6 completed

About this Calculator

CNS recurrence/progression in patients with DLBCL can be devastating. Although some studies suggest a decline in the occurrence of CNS relapse in the rituximab era, certain high risk groups can still be identified and should be considered for CNS-directed trials or prophylactic therapies.

The CNS-IPI was derived from a population of patients (n=2164) enrolled in the German clinical trials and subsequently validated in a population of 1597 patients treated in British Columbia, Canada. The score is based on the original IPI factors with the addition of kidney and/or adrenal involvement. The final score is able to differentiate patients into 3 distinct prognostic groups for CNS recurrence/progression.

References

Schmitz, et al.

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2016 September 10, 34 (26): 3150-6

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.